Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Pancreatic Cancer
This study is looking at a new way to diagnose pancreatic cancer using a method called chromatin immunoprecipitation (ChIP). This technique examines how proteins and DNA interact in the body. Researchers hope to use this method to find pancreatic cancer early and predict how it might progress. This is a non-human subject research study, meaning it uses de-identified (anonymous) samples from people who have already been diagnosed with pancreatic cancer. The main goal is to measure the level of a specific marker called c-ERBB1 in blood samples using ChIP and another test called RT-qPCR. The study aims to enroll 24 participants. You may be able to participate if you are 18 years or older and have pancreatic cancer.
- Study design
- This is an observational study that is not specified by phase, with a planned enrollment of 24 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, measuring c-ERBB1 levels, will be assessed at 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Kersten Schroeder, PhD · PRINCIPAL_INVESTIGATOR · University of Central Florida
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Level of c-ERBB1 in blood using Chromatin immunoprecipitation and Reverse transcription-quantitative polymerase chain reaction1 year
Chromatin immunoprecipitation is a method used to study the interaction between DNA and proteins. This makes it a valuable tool for detecting disease state in samples as it allows us to study gene regulation. To put this into practice, DNA is crosslinked to proteins and precipitated out of solution using an antibody. In this case, anti-H3K36me3 was used as it is a marker for active gene regulation which allows for separation of actively transcribed genes. This is synonymous to selecting for a certain disease state that is ongoing. Once this is done, Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is run on the sample to select for EGFR c-ERBB1, which is an epithelial growth factor (EGFR) mutation which is present in 93% of PDAC cases. Analysis of relative levels of c-ERBB1 should allow for us to diagnose and prognose different stages of PDAC.